HAI-ROBOTICS
14.12.2021 14:22:13 CET | Business Wire | Press release
HAI ROBOTICS , a global leader in Autonomous Case-handling Robotics (ACR) system for warehouse fulfillment, marked a milestone for its solution of HAIPORT-powered Workstation -- with over 100 sets in operation globally since the product was launched one year ago. The solution has enormously improved order fulfillment efficiency for its customers who were pressured to update their warehousing facilities with higher throughput capacity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005725/en/
HAIPORT is an automatic loading and unloading machine that can be docked with HAI ROBOTICS’ autonomous case-handling robots and conveyor workstations.
At a HAIPORT-powered Workstation, multiple loads of totes or cartons are unloaded from the HAIPICK robots at the HAIPORT loader, then transferred onto the conveyor belts for sorting per system orders and moved to the HAIPORT unloader, where they were fetched by robots for the next round of order processing.
The collaboration between HAIPICK robots, HAIPORT, and conveyor belt allows one-stop case-handling from in-bounds to out-bounds. The solution boasts obvious advantages by increasing the throughput of a warehouse.
With case loading and unloading being processed simultaneously at the two sides of a HAIPORT, a single workstation can be expected to handle up to 900 cases per hour, far exceeding that of manual handling. The speed is 16 times faster than the robot-to-conveyor belt transport.
The speed - four to eight cases being loaded in 3 seconds and unloaded in 5s - promises higher case-handling capacity. A single robot’s efficiency can be improved by 30% compared with manual loading/unloading.
Designed to realize direct interaction between HAIPICK robot and conveyor belt, HAIPORT-powered workstation guarantees higher loading and unloading speeds with least human intervention, increasing manual picking efficiency up to 3 times. The use of the workstation can free warehouse staff from tedious manual labor so that they can focus on more important tasks.
Armed with HAI ROBOTICS’ software platform as well as the multi-sensor technology that can monitor a robot’s movement, the workstation can accurately judge if a particular case of goods should be delivered to a workstation or not. Its modular design also grants scalability and flexibility when automating a warehouse. It can be customized and adapted for different uses based on the customer’s requirements. As a result, 30% fewer robots are required if a HAIPORT-powered Workstation is deployed in a warehouse.
HAIPORT-powered workstation has been certified by CE and ETL in compliance with the safety standards for Europe and US markets, respectively. The certifications also evidence that HAI ROBOTICS has been implementing stringent quality control for its products along its own supply chain, in product design and production.
Jeff Zheng, R&D Director at HAI ROBOTICS, said, “HAIPORT-powered Workstation offers an innovative solution for warehousing automation and provides a new way of human-machine interaction. It helps not only increase operational efficiency, but also reduce costs and deliver better ROI. We’re committed to delivering more value to our customers and making their investments worthwhile.”
Thanks to its flexibility, HAIPORT-powered Workstation is suitable for extensive storage scenarios in which medium and small-sized cases are used, such as raw materials, small electronics, apparels, medicine, retails and 3PL industries that have large number of SKUs and demand high order fulfillment efficiency in peak hours with surging e-commerce demands.
About HAI ROBOTICS
HAI ROBOTICS, a trailblazer of Autonomous Case-handling Robot (ACR) system, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse.
The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.
Founded in 2016 with headquarters in Shenzhen, China, HAI ROBOTICS has set up five subsidiaries in Hong Kong SAR, Japan, Singapore, the U.S. and the Netherlands, serving customers from more than 30 countries and regions. It now has over 1,200 staff, more than 50% of whom are engineers. The company has acquired more than 600 global patents for core intellectual properties involving positioning, robot control and warehouse management. In the latest C and D rounds of funding in 2021, the company raised over US$200 million in total.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005725/en/
Link:
Social Media:
https://www.facebook.com/HAIROBOTICS/videos/?ref=page_internal
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom